MoonLake Immunotherapeutics
MLTX52.670USD
-0.250-0.47%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.34BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MoonLake Immunotherapeutics Unternehmen
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Unternehmensinformationen
BörsenkürzelMLTX
Name des UnternehmensMoonLake Immunotherapeutics
IPO-datumOct 20, 2020
CEODr. Jorge Santos Da Silva
Anzahl der mitarbeiter100
WertpapierartOrdinary Share
GeschäftsjahresendeOct 20
AddresseDorfstrasse 29
StadtZUG
BörseNASDAQ Capital Market Consolidated
LandSwitzerland
Postleitzahl6300
Telefon41415108022
Websitehttps://moonlaketx.com/
BörsenkürzelMLTX
IPO-datumOct 20, 2020
CEODr. Jorge Santos Da Silva
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.08M
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
616.67K
--
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.08M
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
616.67K
--
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Jul 28
Aktualisiert: Mon, Jul 28
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
31.12%
Cormorant Asset Management, LP
13.38%
Fidelity Management & Research Company LLC
8.55%
Reich (Kristian)
4.85%
Santos da Silva (Jorge)
4.85%
Other
37.25%
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
31.12%
Cormorant Asset Management, LP
13.38%
Fidelity Management & Research Company LLC
8.55%
Reich (Kristian)
4.85%
Santos da Silva (Jorge)
4.85%
Other
37.25%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
52.91%
Investment Advisor
20.80%
Investment Advisor/Hedge Fund
18.92%
Individual Investor
10.94%
Corporation
4.39%
Research Firm
2.38%
Venture Capital
1.46%
Pension Fund
0.08%
Bank and Trust
0.07%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
325
71.13M
112.06%
-8.47M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
2023Q1
123
42.29M
108.00%
-6.15M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BVF Partners L.P.
19.75M
31.12%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
8.49M
13.38%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.43M
8.55%
-59.34K
-1.08%
Mar 31, 2025
Reich (Kristian)
3.08M
4.85%
--
--
Mar 15, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
T. Rowe Price Associates, Inc.
2.97M
4.69%
-369.81K
-11.06%
Mar 31, 2025
MoonLake Immunotherapeutics AG
2.79M
4.39%
+2.69M
+2715.67%
Dec 31, 2023
Avoro Capital Advisors LLC
2.77M
4.36%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.48M
2.33%
-708.23K
-32.39%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.43M
2.26%
+123.15K
+9.39%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ALPS Medical Breakthroughs ETF
2.03%
Global X Guru Index ETF
1.53%
Harbor Health Care ETF
1.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Goldman Sachs Future Health Care Equity ETF
0.63%
iShares Health Innovation Active ETF
0.13%
Nuveen ESG Small-Cap ETF
0.1%
T Rowe Price Small-Mid Cap ETF
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
Strive Small-Cap ETF
0.07%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil2.03%
Global X Guru Index ETF
Anteil1.53%
Harbor Health Care ETF
Anteil1.36%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.97%
Goldman Sachs Future Health Care Equity ETF
Anteil0.63%
iShares Health Innovation Active ETF
Anteil0.13%
Nuveen ESG Small-Cap ETF
Anteil0.1%
T Rowe Price Small-Mid Cap ETF
Anteil0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.09%
Strive Small-Cap ETF
Anteil0.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
